Observations from the CREDO-Kyoto three-vessel disease registry: can one adjust for the unadjustable?

Vasim Farooq; Patrick W. Serruys

doi:10.4244/eijv9i4a68

Related publications

Article2021

TCT-492 External Validation of the SYNTAX Score II 2020 in the CREDO-Kyoto PCI/CABG Registry

Hironori Hara, Hiroki Shiomi, David van Klaveren, David M. Kent, Ewout W. Steyerberg, Scot Garg, Yoshinobu Onuma, Takeshi Kimura, Patrick W. Serruys

Journal of the American College of Cardiology

Article2012

Freeing the vessel from metallic cage: what can we achieve with bioresorbable vascular scaffolds?

Yoshinobu Onuma, Takashi Muramatsu, Alexander Kharlamov, Patrick W. Serruys

Cardiovascular Intervention and Therapeutics

Article2019

TCT-111 Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for Three Vessel Disease

Norihiro Kogame, Kuniaki Takahashi, Mariusz Tomaniak, Ply Chichareon, Rodrigo Modolo, Yuki Katagiri, Taku Asano, Rod Stables, Simon Walsh, Manel Sabaté, Justin E. Davies, Jan J. Piek, Robert‐Jan van Geuns, Johan Reiber, Vasim Farooq, Adrian Banning, Javier Escaned, Patrick W. Serruys, Yoshinobu Onuma

Journal of the American College of Cardiology

Article2010

TWO-YEAR GRAFT OCCLUSION AND STENT THROMBOSIS IN PATIENTS WITH DE NOVO LEFT MAIN AND/OR THREE VESSEL DISEASE: ANALYSIS FROM THE SYNTAX TRIAL

Ted Feldman, Michael J. Mack, Antonio Colombo, Friedrich W. Mohr, Patrick W. Serruys, A. Pieter Kappetein, Thomas McGarry, Scott K. Lucas, Andrea Maria D’Armini, Ezio Bramucci, Katrin Leadley, Keith D. Dawkins

Journal of the American College of Cardiology

Article2012

TCT-43 Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease

Friedrich Mohr, Simon Redwood, G E Venn, Antonio Colombo, Michael J. Mack, A. Pieter Kappetein, Marie‐Claude Morice, David R. Holmes, Ted Feldman, Elisabeth Ståhle, Keith D. Dawkins, Patrick W. Serruys

Journal of the American College of Cardiology

Observations from the CREDO-Kyoto three-vessel disease registry: can one adjust for the unadjustable?

Abstract

Discussion(0)

Related publications

TCT-492 External Validation of the SYNTAX Score II 2020 in the CREDO-Kyoto PCI/CABG Registry

Freeing the vessel from metallic cage: what can we achieve with bioresorbable vascular scaffolds?

TCT-111 Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for Three Vessel Disease

TWO-YEAR GRAFT OCCLUSION AND STENT THROMBOSIS IN PATIENTS WITH DE NOVO LEFT MAIN AND/OR THREE VESSEL DISEASE: ANALYSIS FROM THE SYNTAX TRIAL

TCT-43 Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease